A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some ...
Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI ...
A small study found a 10-week ketogenic diet was associated with a roughly 70% decrease in depression symptoms, improved well ...
DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated before the end of 2025Trial builds on positive Phase 1 ...
Ammoxetine, a novel SNRI developed from duloxetine, was effective at treating adults with major depressive disorder (MDD) and ...
Catastrophic damage will occur: A high percentage of framed homes will be destroyed, with total roof failure and wall collapse. Fallen trees and power poles will isolate residential areas. Power ...
Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...
Skye Bioscience is rated Buy, driven by nimacimab’s strong safety, durable weight-loss profile, and upcoming Phase 2a results ...
Clinical Trials Arena on MSN
Trials to watch: Three major catalysts in Alzheimer’s disease
While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
On Sunday September 29, the flagship Forbes Under 30 Summit kicked off in Columbus, Ohio, bringing together the brightest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback